Nurix Therapeutics, Inc. (NRIX) Balance Sheet
NRIX balance sheet, FY2025
November 30, 2025 · U.S. dollars$688.1M assets = $149.4M liabilities + $538.7M equity
Both columns are drawn to the same scale: what NRIX owns equals what it owes plus shareholders’ equity. Hover a block for its value.
NRIX financial health
Descriptive bands, not a rating. Fiscal FY2025.
NRIX balance sheet trends, FY2018–FY2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $45.4MFY2018 | $688.1MFY2025 | +47.5%/yr | |
| Total liabilities | $34.0MFY2018 | $149.4MFY2025 | +23.5%/yr | |
| Shareholders’ equity | −$36.8MFY2018 | $538.7MFY2025 | — | |
| Cash & short-term investments | $39.0MFY2018 | $592.9MFY2025 | +47.5%/yr | |
| Total debt | $2.8MFY2018 | $55.7MFY2025 | +53.0%/yr | |
| Net cash (debt) | $36.2MFY2018 | $537.2MFY2025 | +$501.0M | |
| Working capital | $7.8MFY2018 | $520.3MFY2025 | +$512.5M | |
| Book value per share | −$1.49FY2019 | $6.22FY2025 | — | |
| Current ratio | 1.24FY2018 | 7.02FY2025 | +5.78 | |
| Debt / equity | 0.03FY2020 | 0.10FY2025 | +0.08 | |
| Shares outstanding | 38.8MFY2019 | 86.7MFY2025 | +14.3%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
NRIX assets
NRIX liabilities and equity
NRIX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
NRIX balance sheet
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & short-term investments | $592.9M | $609.6M | $287.9M | $309.1M | $295.7M | $281.1M | $37.7M | $39.0M |
| Cash & equivalents | $247.0M | $110.0M | $54.6M | $64.5M | $80.5M | $119.4M | $34.8M | $25.6M |
| Short-term investments | $346.0M | $499.6M | $233.3M | $244.7M | $215.2M | $161.8M | $2.9M | $13.4M |
| Receivables | $0 | $1.5M | $800,000 | $1.1M | $6.2M | $11.3M | $0 | $0 |
| Inventory | $0 | $0 | $0 | −$1.1M | $1 | $0 | $0 | $0 |
| Other current assets | $13.9M | $8.3M | $6.8M | $9.3M | $9.2M | $5.9M | $1.6M | $1.6M |
| Total current assets | $606.8M | $619.4M | $295.5M | $318.4M | $311.1M | $298.4M | $39.4M | $40.7M |
| Property, plant & equipment (net) | $73.0M | $45.9M | $48.0M | $29.5M | $25.3M | $6.7M | $3.9M | $4.4M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $7.4M | $63.9M | $137.2M | $90.9M | $506,000 | $0 |
| Other non-current assets | $8.3M | $4.1M | $4.7M | $4.9M | $3.1M | $347,000 | $317,000 | $321,000 |
| Total assets | $688.1M | $669.3M | $355.6M | $416.8M | $476.8M | $396.3M | $44.0M | $45.4M |
| Liabilities | ||||||||
| Accounts payable | $11.2M | $11.5M | $6.4M | $5.1M | $6.7M | $3.4M | $1.6M | $1.3M |
| Short-term debt | $2.8M | $8.0M | $7.5M | $5.5M | $3.8M | $7.6M | $4.6M | $2.8M |
| Deferred revenue | $17.6M | $38.4M | $48.1M | $37.6M | $41.2M | $32.8M | $9.6M | $28.4M |
| Total current liabilities | $86.5M | $95.9M | $87.0M | $70.7M | $66.3M | $44.5M | $16.1M | $32.8M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $55.7M | $28.3M | $30.6M | $12.0M | $13.0M | $0 | — | — |
| Other long-term liabilities | $62.9M | $46.5M | $68.1M | $42.4M | $68.2M | $61.5M | $85.6M | $49.4M |
| Total liabilities | $149.4M | $142.3M | $155.1M | $113.1M | $134.5M | $106.1M | $53.6M | $34.0M |
| Shareholders' equity | ||||||||
| Common stock & paid-in capital | $102,000 | $76,000 | $49,000 | $47,000 | $45,000 | $39,000 | $4,000 | $3,000 |
| Retained earnings (deficit) | −$1.00B | −$738.8M | −$545.2M | −$401.3M | −$220.9M | −$103.7M | −$60.5M | −$38.8M |
| Accumulated other comprehensive income | $105,000 | $150,000 | −$655,000 | −$4.3M | −$608,000 | $87,000 | −$2,000 | −$4,000 |
| Total shareholders' equity | $538.7M | $527.0M | $200.5M | $303.7M | $342.3M | $290.3M | −$57.7M | −$36.8M |
| Key figures | ||||||||
| Total debt | $55.7M | $28.3M | $30.6M | $12.0M | $13.0M | $7.6M | $4.6M | $2.8M |
| Net cash (debt) | $537.2M | $581.3M | $257.3M | $297.2M | $282.7M | $273.5M | $33.1M | $36.2M |
| Working capital | $520.3M | $523.5M | $208.5M | $247.8M | $244.9M | $253.9M | $23.2M | $7.8M |
| Tangible book value | $538.7M | $527.0M | $200.5M | $303.7M | $342.3M | $290.3M | −$57.7M | −$36.8M |
| Book value per share | $6.22 | $7.85 | $3.69 | $6.25 | $7.98 | — | −$1.49 | — |
| Shares outstanding | 86.7M | 67.1M | 54.3M | 48.6M | 42.9M | — | 38.8M | — |
| Current ratio | 7.02 | 6.46 | 3.40 | 4.51 | 4.70 | 6.70 | 2.44 | 1.24 |
| Quick ratio | 6.86 | 6.38 | 3.32 | 4.39 | 4.56 | 6.57 | 2.34 | 1.19 |
| Debt / equity | 0.10 | 0.05 | 0.15 | 0.04 | 0.04 | 0.03 | — | — |
| Equity / assets | 78.3% | 78.7% | 56.4% | 72.9% | 71.8% | 73.2% | −131.0% | −81.2% |
| Aug '26 | May '26 | Feb '26 | Nov '25 | Aug '25 | May '25 | Feb '25 | Nov '24 | Aug '24 | May '24 | Feb '24 | Nov '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $1.05B | $443.5M | $540.7M | $592.9M | $428.8M | $485.8M | $549.7M | $609.6M | $448.1M | $443.1M | $244.0M | $287.9M |
| Cash & equivalents | $720.2M | $67.7M | $71.2M | $247.0M | $78.4M | $84.3M | $75.9M | $110.0M | $99.0M | $116.8M | $49.8M | $54.6M |
| Short-term investments | $328.0M | $375.8M | $469.5M | $346.0M | $350.4M | $401.5M | $473.8M | $499.6M | $349.0M | $326.3M | $194.2M | $233.3M |
| Receivables | $20.0M | $0 | $2.4M | $0 | $1.7M | $19.0M | $9.1M | $1.5M | $800,000 | $600,000 | $800,000 | $800,000 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | −$800,000 | $0 | $0 | $0 |
| Other current assets | $35.4M | $13.0M | $11.3M | $13.9M | $10.1M | $10.5M | $4.9M | $8.3M | $8.0M | $6.5M | $6.2M | $6.8M |
| Total current assets | $1.10B | $456.5M | $554.4M | $606.8M | $440.6M | $515.3M | $563.7M | $619.4M | $456.0M | $450.2M | $251.0M | $295.5M |
| Property, plant & equipment (net) | $68.0M | $70.1M | $73.4M | $73.0M | $73.5M | $69.0M | $44.8M | $45.9M | $44.2M | $47.4M | $47.2M | $48.0M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $9.5M | $9.4M | $10.3M | $7.4M |
| Other non-current assets | $23.6M | $8.9M | $8.4M | $8.3M | $8.3M | $7.2M | $6.5M | $4.1M | $3.9M | $4.0M | $4.2M | $4.7M |
| Total assets | $1.20B | $535.5M | $636.1M | $688.1M | $522.5M | $591.6M | $615.0M | $669.3M | $513.6M | $511.0M | $312.7M | $355.6M |
| Liabilities | ||||||||||||
| Accounts payable | $33.0M | $12.2M | $10.3M | $11.2M | $8.6M | $6.0M | $8.4M | $11.5M | $3.9M | $2.8M | $5.9M | $6.4M |
| Short-term debt | $3.2M | $3.2M | $3.2M | $2.8M | $3.8M | $5.2M | $6.6M | $8.0M | $6.6M | $7.9M | $7.3M | $7.5M |
| Deferred revenue | $8.6M | $13.3M | $18.8M | $17.6M | $26.0M | $27.4M | $30.6M | $38.4M | $48.0M | $46.8M | $46.1M | $48.1M |
| Total current liabilities | $130.7M | $72.0M | $92.2M | $86.5M | $82.3M | $75.6M | $90.0M | $95.9M | $86.3M | $80.8M | $87.6M | $87.0M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | — | $58.1M | $58.7M | $55.7M | $56.5M | $51.9M | $26.6M | $28.3M | $27.1M | $28.8M | $29.2M | $30.6M |
| Other long-term liabilities | $96.2M | $60.9M | $63.0M | $62.9M | $67.9M | $68.3M | $44.1M | $46.5M | $50.4M | $59.6M | $56.3M | $68.1M |
| Total liabilities | $227.0M | $132.9M | $155.2M | $149.4M | $150.2M | $144.0M | $134.1M | $142.3M | $136.7M | $140.3M | $143.9M | $155.1M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $109,000 | $104,000 | $103,000 | $102,000 | $77,000 | $76,000 | $76,000 | $76,000 | $67,000 | $64,000 | $49,000 | $49,000 |
| Retained earnings (deficit) | −$630.1M | −$1.18B | −$1.09B | −$1.00B | −$925.0M | −$838.6M | −$795.1M | −$738.8M | −$680.2M | −$631.3M | −$586.7M | −$545.2M |
| Accumulated other comprehensive income | −$210,000 | −$145,000 | $56,000 | $105,000 | $119,000 | −$20,000 | $226,000 | $150,000 | $344,000 | −$135,000 | −$350,000 | −$655,000 |
| Total shareholders' equity | $968.3M | $402.6M | $480.9M | $538.7M | $372.3M | $447.6M | $480.9M | $527.0M | $376.9M | $370.7M | $168.7M | $200.5M |
| Key figures | ||||||||||||
| Total debt | $65.3M | $58.1M | $58.7M | $55.7M | $56.5M | $51.9M | $26.6M | $28.3M | $27.1M | $28.8M | $29.2M | $30.6M |
| Net cash (debt) | $982.9M | $385.4M | $482.1M | $537.2M | $372.3M | $433.9M | $523.1M | $581.3M | $420.9M | $414.3M | $214.8M | $257.3M |
| Working capital | $973.0M | $384.5M | $462.2M | $520.3M | $358.3M | $439.7M | $473.7M | $523.5M | $369.7M | $369.4M | $163.3M | $208.5M |
| Tangible book value | $968.3M | $402.6M | $480.9M | $538.7M | $372.3M | $447.6M | $480.9M | $527.0M | $376.9M | $370.7M | $168.7M | $200.5M |
| Book value per share | $8.34 | $3.62 | $4.37 | $5.67 | $4.42 | $5.34 | $5.76 | $6.72 | $5.18 | $5.94 | $3.07 | $3.67 |
| Shares outstanding | 116.2M | 111.1M | 110.1M | 95.1M | 84.2M | 83.9M | 83.6M | 78.4M | 72.8M | 62.4M | 54.9M | 54.7M |
| Current ratio | 8.44 | 6.34 | 6.01 | 7.02 | 5.35 | 6.82 | 6.26 | 6.46 | 5.28 | 5.57 | 2.86 | 3.40 |
| Quick ratio | 8.17 | 6.16 | 5.89 | 6.86 | 5.23 | 6.68 | 6.21 | 6.38 | 5.20 | 5.49 | 2.79 | 3.32 |
| Debt / equity | 0.07 | 0.14 | 0.12 | 0.10 | 0.15 | 0.12 | 0.06 | 0.05 | 0.07 | 0.08 | 0.17 | 0.15 |
| Equity / assets | 81.0% | 75.2% | 75.6% | 78.3% | 71.2% | 75.7% | 78.2% | 78.7% | 73.4% | 72.5% | 54.0% | 56.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed January 28, 2026); data from EODHD.
NRIX financial position
At the end of fiscal 2025 (November 30, 2025), Nurix Therapeutics had total assets of $688.1 million (up 2.8% from a year earlier), total liabilities of $149.4 million and shareholders' equity of $538.7 million. It held $592.9 million in cash and short-term investments against $55.7 million of debt, a net cash position of $537.2 million. Its current ratio was 7.02. In the latest quarter (ended August 31, 2026) total assets were $1.2 billion and equity $968.3 million.
Related: NRIX income statement, NRIX cash flow statement, NRIX key metrics. See the NRIX stock overview for the latest quote and news.
NRIX balance sheet FAQ
What are Nurix Therapeutics's total assets?
Nurix Therapeutics reported total assets of $688.1 million at the end of fiscal 2025 (November 30, 2025), compared with $669.3 million a year earlier.
How much debt does Nurix Therapeutics have?
Nurix Therapeutics had $55.7 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.10.
How much cash does Nurix Therapeutics have?
Nurix Therapeutics held $592.9 million in cash and short-term investments at the end of fiscal 2025; with $55.7 million of debt that is net cash of $537.2 million.
What is Nurix Therapeutics's book value?
Nurix Therapeutics's shareholders' equity (book value) was $538.7 million at the end of fiscal 2025, or $6.22 per share.
What is Nurix Therapeutics's current ratio?
Nurix Therapeutics had current assets of $606.8 million and current liabilities of $86.5 million, a current ratio of 7.02 (it can cover its short-term obligations).